Novel Approaches to Target MECOM/EVI1 in AML
ConditionAML, Adult
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
AML with MECOM or atypical 3q26 rearrangements.
Age ≥18.
Signed written informed consent according to ICH/EU/GCP and national local laws.
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
Biological characterization of AML with MECOM or atypical 3q26 rearrangements
Biological/VaccinePeripheral blood and bone marrow withdrawal
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable
To assess the number of regulators or effectors of MECOM/EVI1
Time frame
At baselineSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov